M&A / Property Routine +

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 08:00 4875 NaN

Executive Summary

MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of MN-166 (ibudilast) in combination with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment.
The patent expires no earlier than September 2042 and covers broad treatment parameters, including dosing regimens, administration routes, duration, and dose levels.
This follows a pattern of recent pipeline updates: April 2026 research highlighted MN-166's ability to block the MIF-CD74 axis to suppress brain metastasis, and May 2026 marked the completion of the last patient last visit for the MN-001 Phase 2 trial.
The company continues to advance MN-166 in late-stage neurology trials (COMBAT-ALS for ALS, OXTOX for CIPN) and is expanding its oncology focus into combination immunotherapy strategies.

Material Impact

The patent allowance is a standard intellectual property milestone that secures regulatory and commercial protection for a specific combination therapy. It does not alter clinical trial timelines, regulatory pathways, or near-term cash requirements.
It provides foundational IP support for rational combination strategies in glioblastoma, an area with high unmet need but historically difficult clinical outcomes. The broad claims reduce the risk of design-around by competitors.
There is no immediate financial impact, no new partnership announced, and no change to the company's capital allocation strategy. The news is defensive and incremental rather than transformative.

4875 · Price

Company Overview

MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
Lead assets include MN-166 (ibudilast) and MN-001 (tipelukast), both demonstrating strong safety profiles and multi-modal mechanisms of action.
Pipeline highlights:
MN-166: Phase 3 trials for ALS and degenerative cervical myelopathy; Phase 3-ready for progressive MS; Phase 2 for CIPN and Long COVID; expanding into oncology (glioblastoma, brain metastases).
MN-001: Phase 2 trial for hypertriglyceridemia and NAFLD associated with type 2 diabetes.
Regulatory designations for MN-166 include Orphan Drug Designation (FDA & EMA) and Fast Track Designation (FDA) for ALS.

More from NaN